You are here: Industry Insights > Vadadustat

News List

Akebia Announces Otsuka's Submission of Initial Marketing Authorization Application to the European Medicines Agency for Vadadustat for the Treatment of Patients with Anemia due to Chronic Kidney Dise prnewswire
November 01, 2021
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, and its collaborator, Otsuka Pharmaceutical Co., Ltd. (Otsuka)...
Akebia and Otsuka Announce FDA Acceptance for Filing of New Drug Application for Vadadustat for the Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis and Not on Dialysis drugs
June 21, 2021
Akebia today announced that the U.S. Food and Drug Administration accepted for filing the New Drug Application for vadadustat for the treatment of anemia due to chronic kidney disease in both adult patients on dialysis and adult patients not on dialysis.
Akebia Announces Top-Line Results from Vadadustat Study americanpharmaceuticalreview
September 07, 2020
Akebia Therapeutics announces top-line results from PRO2TECT, the second of its two global Phase 3 cardiovascular outcomes programs.
Akebia Begins Investigator-Sponsored Vadadustat Study for ARDS in COVID-19 americanpharmaceuticalreview
July 23, 2020
Akebia Therapeutics announced the initiation of an investigator-sponsored study evaluating the use of vadadustat, Akebia's investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), as a potential therapy to prevent and ...